Peptide head-to-head comparisons.
Side-by-side reference pages for the peptide pairings researchers most often ask about. Mechanism, trial data, dose schedules, and FDA status laid out cleanly — neutral, cited, educational.
Why we publish these as their own pages
The most common shape of a real research question is "what's the difference between X and Y?" — the framing assumes the user already knows what they're weighing and just wants the differences laid out compactly. Per-peptide pages do a good job of describing one compound; a dedicated comparison page does a better job of describing the gap between two.
Each comparison includes a quick-facts table covering mechanism, FDA status, dose range, and side-effect profile, then several long-form sections going deeper on specific trade-offs. Every quantitative figure is sourced — typically to a PubMed-indexed paper or an FDA-approved product label.
The pages do not recommend one peptide over the other. The framing is consistent with the rest of the site: educational reference for researchers and laboratory professionals working with peptide reference data. Products covered are research only; the site does not address human use, prescribed therapy, or patient self-administration.
Growth-hormone-secretagogue comparisons
- Sermorelin vs IpamorelinGHSSermorelin · Ipamorelin
Side-by-side reference for sermorelin vs ipamorelin: GHRH analogue vs ghrelin mimetic mechanism, dose schedules, side effects, FDA history, and why they are commonly stacked.
- Ipamorelin vs TesamorelinGHSIpamorelin · Tesamorelin
Side-by-side reference for ipamorelin vs tesamorelin: ghrelin mimetic vs stabilized GHRH analogue, FDA-approved Egrifta indication, dose schedules, side effects.
- CJC-1295 vs SermorelinGHSCJC-1295 · Sermorelin
Side-by-side reference for CJC-1295 vs sermorelin: both GHRH analogues, but with very different half-lives (and DAC variants). Pulsatility, dose frequency, and FDA history compared.
Frequently asked questions about comparisons
- Why are comparison pages useful?
- Most decisions in a research-peptide context are framed as choices between two specific compounds — semaglutide vs tirzepatide, BPC-157 vs TB-500, ipamorelin vs sermorelin. A comparison page surfaces mechanism, dose, FDA status, and side-effect data side by side so the trade-offs are visible without bouncing between two separate peptide pages.
- Are these recommendations?
- No. Each comparison summarises published trial data, FDA labels, and peer-reviewed mechanism literature for the two peptides. The pages do not recommend one peptide over another — that decision belongs with a licensed prescriber, principal investigator, or research protocol owner.
- How are the comparison pairs chosen?
- Pairs are chosen for high search intent and obvious relevance — peptides that share a category, a stack, or an overlapping use case. We add pairs as the underlying peptide library grows, and we update existing pages as new trial data is published.
- Where does the calculator math come from?
- Every comparison page links to both component peptide pages, where the same calculator is preset to that peptide's typical vial and BAC water values. The calculator math is pure functions in src/lib/calc.ts and is unit-tested.
PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.